1. Detection of Artemisinin Resistance Marker Kelch-13 469Y in Plasmodium falciparum, South Kivu, Democratic Republic of the Congo, 2022.
- Author
-
van Loon W, Bisimwa BC, Byela V, Kirby R, Bugeme PM, Balagizi A, Lupande D, Malembaka EB, Mockenhaupt FP, and Bahizire E
- Subjects
- Humans, Plasmodium falciparum, Democratic Republic of the Congo epidemiology, Lumefantrine therapeutic use, Uganda, Drug Resistance genetics, Protozoan Proteins genetics, Antimalarials pharmacology, Antimalarials therapeutic use, Artemisinins pharmacology, Artemisinins therapeutic use, Malaria, Falciparum drug therapy, Malaria, Falciparum epidemiology
- Abstract
Partial artemisinin resistance has emerged in East Africa, posing a threat to malaria control across the continent. The Democratic Republic of the Congo carries one of the heaviest malaria burdens globally, and the South Kivu province directly borders current artemisinin resistance hot spots, but indications of such resistance have not been observed so far. We assessed molecular markers of antimalarial drug resistance in 256 Plasmodium falciparum isolates collected in 2022 in South Kivu, Democratic Republic of the Congo. One isolate carried the P. falciparum Kelch-13 469Y variant, a marker associated with partial artemisinin resistance and decreased lumefantrine susceptibility in Uganda. In addition, the multidrug resistance-1 mutation pattern suggested increased lumefantrine tolerance.
- Published
- 2024
- Full Text
- View/download PDF